Two separate works are part of the MATRIX study investigating strategies to reduce bleeding and mortality in patients with acute coronary syndrome. The first part of the work that was simultaneously published in The Lancet found a significant reduction in major bleeding and mortality in patients undergoing coronary angiography and angioplasty using radial versus femoral<a href="https://solaci.org/en/2015/06/24/matrix-the-radial-access-reduces-events-bivalirudin-with-mixed-results/" title="Read more" >...</a>

The aim of this study was to assess treatment with the new anticoagulant Pegnivacogin and its specific antidote Anivamersen compared with bivalirudin in patients undergoing coronary angioplasty. The Pegnivacogin has an affinity for factor IXa with a longer shelf life to 24 hours and Anivamersen only has an affinity for Pegnivacogin. The combination of these<a href="https://solaci.org/en/2015/06/24/regulate-pci-reg1-with-an-unacceptable-rate-of-severe-allergic-reactions/" title="Read more" >...</a>

Infarct size is an independent predictor of survival and ventricular function. Several alternatives have been tried to reduce the size of the infarcted area and its consequences. Small pilot studies suggest that inhaled nitric oxide may improve reperfusion in acute myocardial infarction with ST-segment elevation. Patients were randomized to conventional treatment versus inhalation of 80<a href="https://solaci.org/en/2015/06/24/noni-inhaled-nitric-oxide-to-reduce-reperfusion-injury-in-myocardial-infarction/" title="Read more" >...</a>

Statins may help stabilize the atherosclerotic plaque in acute myocardial infarction. 103 patients who underwent primary angioplasty followed by coronary intravascular ultrasound (IVUS) in the culprit artery and not culprit of infarction were included. Patients received 20 mg of rosuvastatin for two weeks and then 40 mg for 13 months ending up with a new<a href="https://solaci.org/en/2015/06/24/ibis-4-intensive-treatment-with-statins-after-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7 centers suffering ST-segment elevation acute myocardial infarction referred for primary angioplasty randomized to treat only the culprit artery (n = 146) versus complete revascularization (n = 150).&nbsp; In the culprit artery<a href="https://solaci.org/en/2015/06/24/culprit-complete-revascularization-versus-culprit-artery-of-infarct-only/" title="Read more" >...</a>

The benefit of myocardial revascularization (angioplasty or surgery) guided by fractional flow reserve (FFR) in the context of acute coronary syndromes is poorly studied in the literature. The aim of this study was to compare myocardial revascularization guided by FFR versus Angiography in patients admitted suffering a non-ST segment elevation myocardial infarction. 350 patients were<a href="https://solaci.org/en/2015/06/24/famous-nstemi-ffr-versus-angiography-in-non-st-segment-elevation-myocardial-infarction/" title="Read more" >...</a>

The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an ST-segment elevation acute myocardial infarction. Pre-hospital management that could improve coronary reperfusion and events like death or stent thrombosis was not studied. 1862 patients were included suffering ST-segment elevation acute myocardial<a href="https://solaci.org/en/2015/06/24/atlantic-administration-of-ticagrelor-in-the-ambulance-versus-in-the-cath-lab/" title="Read more" >...</a>

The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents is unclear. This study aimed to evaluate the clinical non-inferiority at 3 months versus 12 months of dual anti-platelet therapy in patients undergoing coronary angioplasty with zotarolimus-eluting stents. The study randomized 1:1 to 3 months<a href="https://solaci.org/en/2015/06/24/optimize-3-months-versus-12-months-of-dual-anti-aggregation-with-zotarolimus-eluting-stents/" title="Read more" >...</a>

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences clinical outcomes after angioplasty and if the time of double anti-aggregation should be different with the degradable polymer. This work, with non-inferiority design, aimed to compare the sirolimus-eluting biodegradable polymer stent (Tivoli) versus the permanent polymer sirolimus-eluting stent<a href="https://solaci.org/en/2015/06/24/i-love-it2-drug-eluting-stents-with-a-permanent-polymer-versus-biodegradable-in-the-same-cobalt-chromium-platform/" title="Read more" >...</a>

This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus 1 year (n = 717) dual anti-aggregation after implantation of 2nd generation drug-eluting stent. The primary end point was a composite of cardiac death, myocardial infarction, stroke, definite or probable thrombosis, and major bleeding. At 12 months follow-up<a href="https://solaci.org/en/2015/06/24/security-6-months-versus-12-months-of-dual-anti-aggregation-using-2nd-generation-des/" title="Read more" >...</a>